Skip to Content

Associate Zachary D. Caplan Named a 2017 Lawyer on the Fast Track

Posted: April 25, 2017
Practice Areas: Antitrust, Commodities and Options

Berger & Montague, P.C. Associate Zachary D. Caplan has been named a 2017 Lawyer on the Fast Track by The Legal Intelligencer.

Earlier in 2017, The Legal Intelligencer asked the Pennsylvania legal community to submit nominations for its annual Lawyers on the Fast Track honors. Nominations were evaluated by a six-member panel composed of evaluators from all corners of the legal profession and Pennsylvania.

Mr. Caplan is one of only 32 attorneys to receive this honor. The complete list can be viewed here.

Mr. Caplan is an associate in the Antitrust and Commodities practice groups at Berger & Montague.

Since joining Berger & Montague in 2011, he has worked on a variety of matters that have resulted in substantial settlements for the firm's clients.  E.g., Marckbanks Truck Service, Inc. v. Comdata Network, Inc., No. 07-cv-1078 (E.D. Pa.) ($130 million settlement plus significant prospective relief); In re Titanium Dioxide Antitrust Litigation, No. 10-cv-318 (D. Md.) (settlements totaling $163.5 million); In re High Tech Employee Antitrust Litigation, No. 11-cv-2509 (N.D. Cal.) (settlements totaling $435 million).

Mr. Caplan is currently involved in antitrust and commodities class actions alleging manipulation of key financial benchmarks.  E.g., In re Commodity Exchange, Inc., Gold Futures and Options Trading Litigation, No. 14-md-2548 (S.D.N.Y.) ($60 million settlement with one defendant pending court approval); In re Platinum and Palladium Antitrust Litig., No. 14-cv-9391 (S.D.N.Y.); In re Libor-Based Financial Instruments Antitrust Litigation, No. 11-md-2262 (S.D.N.Y.); In re North Sea Brent Crude Oil Futures Litigation, No. 13-cv-8240 (S.D.N.Y.).  He also works on a number of antitrust class actions on behalf of direct purchasers of prescription drugs in which the purchasers allege that pharmaceutical manufacturers have wrongfully kept less expensive generic drugs out of the market.  E.g., In re Loestrin 24 Fe Antitrust Litigation, No. 1:13-md-2472 (D.R.I.); In re Opana ER Antitrust Litigation, No. 14-cv-10151 (N.D. Ill.). Additionally, he plays a major role in Adriana Castro, M.D., P.A., et al. v. Sanofi Pasteur Inc., No. 11-cv-07178 (D.N.J.) ($61.5 million settlement pending court approval), In re Capacitors Antitrust Litigation, No. 14-cv-3264 (N.D. Cal.), and In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 16-md-2724 (E.D. Pa.).

Mr. Caplan is a member of the committee that selects the annual winner of the American Antitrust Institute's Jerry S. Cohen Memorial Writing Award for the best antitrust scholarship.  While in law school, Mr. Caplan was a senior editor of the University of Pennsylvania Journal of Business Law, represented clients in various civil matters as part of the Civil Practice Clinic, and interned with the United States Department of Justice Antitrust Division.